Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting

医学 肿瘤科 内科学 结直肠癌 实体瘤疗效评价标准 转移 队列 进行性疾病 比例危险模型 癌症 回顾性队列研究 免疫检查点 无进展生存期 免疫疗法 疾病 化疗
作者
Bahar Saberzadeh-Ardestani,Jeremy Jones,Robert R. McWilliams,David Tougeron,Þorvarður R. Hálfdánarson,Rosine Guimbaud,Joleen M. Hubbard,Clémence Flecchia,Qian Shi,Emily Alouani,Mohamad Bassam Sonbol,Jonathan Ticku,Zhaohui Jin,Julien Taı̈eb,Frank A. Sinicrope
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:196: 113433-113433 被引量:21
标识
DOI:10.1016/j.ejca.2023.113433
摘要

Only one-half of deficient mismatch repair (d-MMR) metastatic colorectal cancers (mCRC) demonstrate durable responses to immune checkpoint inhibitors (ICIs). Given preclinical data indicating that liver metastases sequester activated CD8+ T cells from systemic circulation, we examined clinical outcome by metastatic site.In a retrospective cohort of patients with d-MMR mCRCs treated at multiple centers in France (n = 66), we sought to validate data from a U.S. cohort, and performed pooled analysis (n = 104). All patients received first-line ICI monotherapy. Metastatic site was analyzed in relationship to tumor response (RECIST version 1.1), and with progression-free survival (PFS) by multivariable stratified Cox regression after adjustment for covariates.Objective responses were achieved in 38/66 (58%) of patients in the validation cohort. Best tumor response included 13 (20%) complete responses (CR), 25 (38%) partial responses (PR), 16 (25%) stable disease, and 11 (17%) progressive disease (PD). One-year and 5-year PFS rates were 73% and 67%, respectively; 18 (27%) patients progressed during immunotherapy. Best tumor response was attenuated in patients with liver metastasis (P = 0.03). Presence of liver metastasis, but not other sites, was associated with significantly poorer PFS after adjustment for covariates (HRadj 2.82; 95%CI, 1.08-7.39; Padj=0.03). In a pooled analysis, liver metastasis remained significantly and independently associated with poorer PFS (HRadj 3.18; 95%CI, 1.52-6.67; Padj=0.002) and with attenuated tumor best response (P = 0.01).Metastasis to the liver, but not other sites, was validated as an independent factor associated with poorer response and survival after ICI treatment in d-MMR mCRCs. These data underscore the need for novel therapeutic strategies in these patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
小潘潘发布了新的文献求助10
1秒前
1秒前
打打的应助被杨儿采纳,获得20
1秒前
初景发布了新的文献求助30
1秒前
核桃发布了新的文献求助10
1秒前
小豆包发布了新的文献求助10
1秒前
天天快乐的应助被义气念柏采纳,获得10
2秒前
wangli完成签到,获得积分10
2秒前
福多多完成签到,获得积分10
2秒前
hang发布了新的文献求助10
2秒前
3秒前
赘婿的应助被yyy采纳,获得10
3秒前
可期99完成签到,获得积分10
3秒前
张祖伦完成签到 ,获得积分10
3秒前
3秒前
wanci的应助被晚霞跌落星河采纳,获得10
3秒前
3秒前
4秒前
打打的应助被晚霞跌落星河采纳,获得10
4秒前
大个的应助被晚霞跌落星河采纳,获得10
4秒前
bkagyin的应助被晚霞跌落星河采纳,获得10
4秒前
汉堡包的应助被晚霞跌落星河采纳,获得10
4秒前
橘子s完成签到,获得积分10
4秒前
成就笑寒发布了新的文献求助10
4秒前
aaaaa完成签到 ,获得积分10
5秒前
6秒前
小码发布了新的文献求助10
6秒前
科目三的应助被开朗的慕儿采纳,获得10
7秒前
LZZ完成签到,获得积分10
7秒前
秋秋完成签到,获得积分10
8秒前
8秒前
大模型的应助被tourist585采纳,获得10
9秒前
dxl发布了新的文献求助10
9秒前
Famiglistmo发布了新的文献求助10
9秒前
彭于晏的应助被丕丕采纳,获得10
9秒前
小赵爱吃冰糖葫芦完成签到,获得积分10
9秒前
10秒前
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182789
求助须知:如何正确求助?哪些是违规求助? 9572127
关于积分的说明 21823190
捐赠科研通 7779423
什么是DOI,文献DOI怎么找? 3433724
关于科研通互助平台的介绍 2557907
邀请新用户注册赠送积分活动 2479845